The following protocol is a phase II study of the combination of the GITR agonist monoclonal antibody INCAGN01876, the anti-PD1 monoclonal antibody INCMGA00012, and SRS for recurrent GBM. We hypothesize that the proposed regimen will be safe and stimulate a robust anti-tumor immune response and result in improved tumor responses. The purpose of this protocol is to determine the efficacy of the combination of INCMGA00012, INCAGN01876, and SRS in recurrent GBM, as measured by the overall objective response rate (ORR). INCAGN01876 (anti-GITR) 300mg will be administered IV every 2 weeks until disease progression, unacceptable toxicity, or 2 years, whichever occurs first. INCMGA00012 (anti-PD1) 500mg will be administered IV every 4 weeks until disease progression, unacceptable toxicity, or 2 years, whichever occurs first.

You may be eligible for this study if you meet the following criteria:

• Conditions: Medical Research
• Age: 99 years or below
• Gender: All